Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 2/2011

01-04-2011 | Viewpoint

ERBB receptors in cancer: signaling from the inside

Author: Carlos L Arteaga

Published in: Breast Cancer Research | Issue 2/2011

Login to get access

Abstract

ERBB receptor tyrosine kinases are activated by ligand-induced dimerization followed by activation and transphosphorylation of their intracellular kinase domains. A recent study by Bill and colleagues demonstrates that receptor transphosphorylation can be regulated from inside the cell by members of the cytohesin protein family. These data highlight a novel mechanism of amplification of ERBB receptor signaling output that may contribute to embryogenesis and cancer progression.
Literature
1.
Bublil EM, Yarden Y: The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol. 2007, 19: 124-134. 10.1016/j.ceb.2007.02.008.CrossRefPubMed
2.
Yarden Y, Schlessinger J: Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation. Biochemistry. 1987, 26: 1434-1442. 10.1021/bi00379a034.CrossRefPubMed
3.
Ferguson KM: Structure-based view of epidermal growth factor receptor regulation. Annu Rev Biophys. 2008, 37: 353-373. 10.1146/annurev.biophys.37.032807.125829.CrossRefPubMedPubMedCentral
4.
Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001, 2: 127-137. 10.1038/35052073.CrossRefPubMed
5.
Chung I, Akita R, Vandlen R, Toomre D, Schlessinger J, Mellman I: Spatial control of EGF receptor activation by reversible dimerization on living cells. Nature. 2010, 464: 783-787. 10.1038/nature08827.CrossRefPubMed
6.
Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J: An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell. 2006, 125: 1137-1149. 10.1016/j.cell.2006.05.013.CrossRefPubMed
7.
Jura N, Endres NF, Engel K, Deindl S, Das R, Lamers MH, Wemmer DE, Zhang X, Kuriyan J: Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell. 2009, 137: 1293-1307. 10.1016/j.cell.2009.04.025.CrossRefPubMedPubMedCentral
8.
Bill A, Schmitz A, Albertoni B, Song JN, Heukamp LC, Walrafen D, Thorwirth F, Verveer PJ, Zimmer S, Meffert L, Schreiber A, Chatterjee S, Thomas RK, Ullrich RT, Lang T, Famulok M: Cytohesins are cytoplasmic ErbB receptor activators. Cell. 2010, 143: 201-211. 10.1016/j.cell.2010.09.011.CrossRefPubMed
9.
Kolanus W: Guanine nucleotide exchange factors of the cytohesin family and their roles in signal transduction. Immunol Rev. 2007, 218: 102-113. 10.1111/j.1600-065X.2007.00542.x.CrossRefPubMed
10.
Sharma SV, Bell DW, Settleman J, Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007, 7: 169-181. 10.1038/nrc2088.CrossRefPubMed
11.
Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE: The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA. 2003, 100: 8933-8938. 10.1073/pnas.1537685100.CrossRefPubMedPubMedCentral
12.
Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX, Stern HM: A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 2008, 68: 5878-5887. 10.1158/0008-5472.CAN-08-0380.CrossRefPubMed
Metadata
Title
ERBB receptors in cancer: signaling from the inside
Author
Carlos L Arteaga
Publication date
01-04-2011
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 2/2011
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2829

Other articles of this Issue 2/2011

Breast Cancer Research 2/2011 Go to the issue

Research article

Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis

Research article

Estrogen receptor beta inhibits transcriptional activity of hypoxia inducible factor-1 through the downregulation of arylhydrocarbon receptor nuclear translocator

Research article

Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action

Research article

miR-24-2 controls H2AFX expression regardless of gene copy number alteration and induces apoptosis by targeting antiapoptotic gene BCL-2: a potential for therapeutic intervention

Research article

Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity

Research article

Breast cancer cell migration is regulated through junctional adhesion molecule-A-mediated activation of Rap1 GTPase
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits